JP2024521412A5 - - Google Patents
Info
- Publication number
- JP2024521412A5 JP2024521412A5 JP2023575800A JP2023575800A JP2024521412A5 JP 2024521412 A5 JP2024521412 A5 JP 2024521412A5 JP 2023575800 A JP2023575800 A JP 2023575800A JP 2023575800 A JP2023575800 A JP 2023575800A JP 2024521412 A5 JP2024521412 A5 JP 2024521412A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- crystalline form
- powder
- ray diffraction
- cukα radiation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110652005.2 | 2021-06-11 | ||
| CN202110652005 | 2021-06-11 | ||
| CN202110690510 | 2021-06-22 | ||
| CN202110690510.6 | 2021-06-22 | ||
| CN202111326112 | 2021-11-10 | ||
| CN202111326112.2 | 2021-11-10 | ||
| PCT/CN2022/096779 WO2022257845A1 (zh) | 2021-06-11 | 2022-06-02 | Tolebrutinib的晶型及其制备方法和用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024521412A JP2024521412A (ja) | 2024-05-31 |
| JP2024521412A5 true JP2024521412A5 (enExample) | 2025-06-10 |
Family
ID=84425691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023575800A Pending JP2024521412A (ja) | 2021-06-11 | 2022-06-02 | トレブルチニブの結晶形並びにその製造方法及び使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250034130A1 (enExample) |
| EP (1) | EP4353723A4 (enExample) |
| JP (1) | JP2024521412A (enExample) |
| KR (1) | KR20240021217A (enExample) |
| CN (1) | CN117897381A (enExample) |
| AU (1) | AU2022290946A1 (enExample) |
| BR (1) | BR112023025841A2 (enExample) |
| CA (1) | CA3221129A1 (enExample) |
| CO (1) | CO2024000054A2 (enExample) |
| IL (1) | IL309263A (enExample) |
| MX (1) | MX2023014722A (enExample) |
| WO (1) | WO2022257845A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3168146A1 (en) | 2020-01-20 | 2021-07-29 | Genzyme Corporation | Therapeutic tyrosine kinase inhibitors for relapsing multiple sclerosis (rms) |
| CA3201936A1 (en) | 2020-12-10 | 2022-06-16 | Minhua Chen | Crystal form of tolebrutinib and preparation method thereof |
| IL303834A (en) | 2020-12-23 | 2023-08-01 | Genzyme Corp | 4-amino-3-(4-phenoxyphenyl)-1,3-dihydro-2H-imidazo[4,5-C]pyridin-2-one derivatives and their salts |
| CA3241687A1 (en) * | 2021-12-21 | 2023-06-29 | Tim Owens | Crystalline forms of (r)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1h-imidazo[4,5-c]pyridin-2(3h)-one and salts thereof |
| US20250188076A1 (en) | 2022-03-09 | 2025-06-12 | Teva Pharmaceutical International Gmbh | Solid state forms of tolebrutinib and of tolebrutinib salts |
| US20240238267A1 (en) * | 2022-12-20 | 2024-07-18 | Genzyme Corporation | Drug formulations of (r)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1h-imidazo[4,5-c]pyridin-2(3h)-one |
| WO2026050513A1 (en) | 2024-08-30 | 2026-03-05 | Principia Biopharma Inc. | Tolebrutinib for multiple sclerosis |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2004001034A1 (es) * | 2003-05-14 | 2005-03-28 | Teijin Pharma Ltd | Formas cristalinas de acido 4-(1-((,etilbenzotiofen-3-il)me til)benzimidazol-2-iltio)butanoico; procedimiento de preparacion de las formas cristalinas; composicion farmaceutica; y su uso para el tratamiento de enfermedades inflamatorias, alergicas, r |
| EP3912979B1 (en) * | 2015-06-03 | 2026-03-25 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| EP3313811A1 (en) * | 2015-06-26 | 2018-05-02 | Aquinox Pharmaceuticals (Canada) Inc. | Crystalline solid forms of the acetate salt of (1s,3s,4r)-4-((3as,4r,5s,7as)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1h-inden-5-yl)-3-(hydroxymethyl)-4-methylcyclohexanol |
| CN105753863B (zh) * | 2015-09-11 | 2018-07-31 | 东莞市真兴贝特医药技术有限公司 | 氧代二氢咪唑并吡啶类化合物及其应用 |
| CA3168146A1 (en) * | 2020-01-20 | 2021-07-29 | Genzyme Corporation | Therapeutic tyrosine kinase inhibitors for relapsing multiple sclerosis (rms) |
-
2022
- 2022-06-02 WO PCT/CN2022/096779 patent/WO2022257845A1/zh not_active Ceased
- 2022-06-02 US US18/568,484 patent/US20250034130A1/en active Pending
- 2022-06-02 JP JP2023575800A patent/JP2024521412A/ja active Pending
- 2022-06-02 AU AU2022290946A patent/AU2022290946A1/en active Pending
- 2022-06-02 KR KR1020247000650A patent/KR20240021217A/ko not_active Withdrawn
- 2022-06-02 MX MX2023014722A patent/MX2023014722A/es unknown
- 2022-06-02 EP EP22819443.7A patent/EP4353723A4/en active Pending
- 2022-06-02 BR BR112023025841A patent/BR112023025841A2/pt unknown
- 2022-06-02 CA CA3221129A patent/CA3221129A1/en active Pending
- 2022-06-02 IL IL309263A patent/IL309263A/en unknown
- 2022-06-02 CN CN202280040545.8A patent/CN117897381A/zh active Pending
-
2024
- 2024-01-04 CO CONC2024/0000054A patent/CO2024000054A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023082086A5 (enExample) | ||
| JP5159788B2 (ja) | １−（β−Ｄ−グルコピラノシル）−４−メチル−３−［５−（４−フルオロフェニル）−２−チエニルメチル］ベンゼン１／２水和物の結晶形 | |
| JP2021530565A5 (enExample) | ||
| US10273262B2 (en) | Crystalline form A of obeticholic acid and preparation method thereof | |
| CN1227233C (zh) | 纯晶形的5－氯－3－(4－甲磺酰基苯基)－6′－甲基－[2,3′]联吡啶及其合成方法 | |
| JP2022183220A5 (enExample) | ||
| JP2019504103A5 (enExample) | ||
| KR20170057441A (ko) | Jak 억제제의 바이설페이트의 결정형 및 이의 제조방법 | |
| JP2019516749A5 (enExample) | ||
| JP2024505063A5 (enExample) | ||
| JP2007520546A (ja) | モンテルカストナトリウムの安定な非晶質性形態 | |
| JP7512405B2 (ja) | ２－［（４ｓ）－８－フルオロ－２－［４－（３－メトキシフェニル）ピペラジン－１－イル］－３－［２－メトキシ－５－（トリフルオロメチル）フェニル］－４ｈ－キナゾリン－４－イル］酢酸のカリウム塩 | |
| CN111278820A (zh) | 一种吡啶酮化合物的晶型、盐型及其制备方法 | |
| JP2026041824A (ja) | テガビビントの結晶形態、調製方法、及びその使用 | |
| TWI808069B (zh) | [(1S)-1-[(2S,4R,5R)-5-(5-胺基-2-酮基-噻唑并[4,5-d]嘧啶-3-基)-4-羥基-四氫呋喃-2-基]丙基]乙酸酯之新穎固態形式 | |
| TW202233205A (zh) | 莫奈皮拉韋之醫藥同質異晶物 | |
| JP7645276B2 (ja) | ２－［（４ｓ）－８－フルオロ－２－［４－（３－メトキシフェニル）ピペラジン－１－イル］－３－［２－メトキシ－５－（トリフルオロメチル）フェニル］－４ｈ－キナゾリン－４－イル］酢酸ナトリウム三水和物の結晶形を製造する方法 | |
| JP2023521631A5 (enExample) | ||
| TW201827436A (zh) | 一種ｊａｋ激酶抑制劑的硫酸氫鹽的晶型及其製備方法 | |
| WO2018072742A1 (zh) | 一种咪唑并异吲哚类衍生物的游离碱的结晶形式及其制备方法 | |
| WO2012071425A1 (en) | Solid state forms of sorafenib besylate, and processes for preparations thereof | |
| JP2023522331A5 (enExample) | ||
| CN111278828A (zh) | 巴瑞替尼磷酸盐的新晶型及其制备方法 | |
| US9920045B2 (en) | Solid state forms of a PDE10 inhibitor | |
| CN114845993A (zh) | 1-(4-苄氧基-苄基)-3-甲基-硫脲的多晶型物 |